# My Journey Towards Understanding the Value of Medical Analytics

Thomas Novicki PhD DABMM
Clinical Microbiologist
Division of Laboratory Medicine

Orchard Analytics Webinar
October 12, 2016



#### **Objectives**

- 1. Explain medical reimbursement trends.
- 2. Describe a medical analytics database.
- 3. List the key resources needed for a medical analytics program.
- 4. Understand what medical analytics can contribute to your institution.



#### **Disclosures**

- I have received no financial or other remuneration from Orchard Software.
- I have no other relevant disclosures.
- These views are those of the presenter, and do not necessarily represent those of Marshfield Clinic or its subsidiaries.



#### → OUT

Fee-for-service payment models

#### $\rightarrow$ IN

Bundled payments incentivized by positive outcomes

#### The Changing Landscape



DAWN OF TIME APRIL 16, 2015

RIP

http://hitconsultant.net/2015/05/11/ death-fee-service-healthcare/. 04/27/16

http://image.slidesharecdn.com/springone2 gx2014holyintegrationtest-141104181654conversion-gate02/95/the-quest-for-the-holyintegration-test-36-638.jpg?cb=1415203147. 04/27/2016



#### The Changing Landscape: 2015

- HHS sets bold new goals
  - By 2018, total Medicare \$\$:
    - 50% value-based alternative payment models
    - 43% value-based FFS
    - > 7% traditional FFS
- Medicare Access and CHIP Reauthorization Act (MACRA) targets FFS & promotes "pay for value".

http://www.hhs.gov/about/news/2015/01/26/better-smarter-healthier-in-historic-announcement-hhs-sets-clear-goals-and-timeline-for-shifting-medicare-reimbursements-from-volume-to-value.html. 4/27/16

https://www.washingtonpost.com/news/wonk/wp/2015/01/26/the-obama-administration-wants-to-dramatically-change-how-doctors-are-paid/. 4/27/16



#### The Changing Landscape: Today

► HHS Health Care Payment Learning and Action
 Network → pushing private payers to value.

#### ➤Now:

➤BC/ BS: 20% of \$\$

➤ Aetna: 28% of \$\$ (going to 78% by 2020)

➤ Medicare Comprehensive Care for Joint Replacement model.

CMS has 27 ongoing model initiatives.

(https://innovation.cms.gov/initiatives/index.html#views=models. 08/10/2016)



#### **Analytics, Defined**

❖ Analytics is the discovery, interpretation, and communication of meaningful patterns in data. Especially valuable in areas rich with recorded information, analytics relies on the simultaneous application of statistics, computer programming and operations research to quantify performance.

(Underscore added.)

(Wikipedia, 08/10/2016)




#### **MA Program Components**

- A willing leadership
- An accepting medical staff
- A well-maintained relational DBMS
- Database analyst
- ❖ A team captain



#### MA – The Process



#### **Post-Analysis**

- The RDMS analysis is often iterative.
- ❖ Data are exportable to Excel.
- Use data internal to the lab (e.g. instrument justification) or externally (e.g. intervention to drive change).
- Post-hoc re-analysis to test intervention.



Copyright © 1999, American Society for Microbiology. All Rights Reserved.

## Clinical and Financial Benefits of Rapid Bacterial Identification and Antimicrobial Susceptibility Testing

JOAN BARENFANGER. 1\* CHERYL DRAKE, 1 AND GAIL KACICH2

Laboratory Medicine<sup>1</sup> and Clinical Data Management, <sup>2</sup> Memorial Medical Center, Springfield, Illinois 62781

Received 30 November 1998/Returned for modification 12 January 1999/Accepted 6 February 1999

- Compared rapid AST reporting to routine AST reporting
  - Analyzed rAST impact on mortality and morbidity
- Mortality rate was unchanged, but mean LoS was reduced by 2 days

Savings: \$4mil / year
(\$5.8mil today)

#### **Fast Forward**

| Winter 2015        | Began conversations with Orchard Analytics. Two pilot projects were selected.                              |
|--------------------|--|
| Spring 2016        | Ran those projects in a two day site visit to Marshfield Clinic.   |
| Summ<br>er<br>2016 | <ul> <li>Presented projects at the OMA annual Symposium</li> <li>Met with Marshfield Clinic CMO</li> </ul> |
| Fall<br>2016       | MC begins it's first MA project: Test utilization in DM pts.   |
|                    | Disclosure: We already had a robust relational Data Warehouse (!)  |



#### **Project 1**

### Thyroid function testing

- ❖Issue:
  - SoC: Screen with TSH; use confirmatory tests only if TSH is abnormal
  - Sub-optimal test utilization leads to wrong diagnoses, missed diagnoses, & excess costs.
- Questions:
  - Are confirmatory TFT tests needlessly used?
  - How often and at what cost?



#### **Project 1**

|   | Annual Volume |      |       | Variable Materials Cost |            |             |
|---|---------------|------|-------|-------------------------|------------|-------------|
| Test Scenario                           |               | MSJH | Total | Clinic                  | MSJH       | Total       |
| FT4 given normal TSH; same req          | 8,835         | 715  | 9,550 | \$26,770.05             | \$2,166.45 | \$28,936.50 |
| FT4 given no TSH                        | 2,041         | 599  | 2,640 | \$6,184.23              | \$1,814.97 | \$7,999.20  |
| FT3 given normal TSH                    | 2,235         | 143  | 2,378 | \$8,805.90              | \$563.42   | \$9,369.32  |
| FT3 given no TSH                        | 650           | 323  | 973   | \$2,561.00              | \$1,272.62 | \$3,833.62  |
| FT3 given high/low TSH and high/low FT4 | 584           | 40   | 624   | \$2,300.96              | \$157.60   | \$2,458.56  |
| TT4 given normal TSH; same req          | 169           | 67   | 236   | \$469.82                | \$186.26   | \$656.08    |
| TT4 given no TSH                        | 49            | 105  | 154   | \$136.22                | \$291.90   | \$428.12    |
| TT3 given normal TSH                    | 8             | 2    | 10    | \$17.84                 | \$4.46     | \$22.30     |
| TT3 given no TSH                        | 1             | 1    | 2     | \$2.23                  | \$2.23     | \$4.46      |
| TT3 given high/low TSH and high/low FT4 | 1             | 1    | 2     | \$2.23                  | \$2.23     | \$4.46      |
| Reverse T3 (all)                        |               | 4    | 83    | \$395.00                | \$20.00    | \$415.00    |
|   |               |      | 16,65 |                         |            |             |
| Total                                   |               |      | 2     |                         |            | \$54,127    |



#### Why MA Now?

Why should I use MA to *reduce* my test volume (and my revenue) when FFS is still here?

- Test utilization committees are demanding it.
- Payers are denying "unnecessary" claims.
- Bundled payments have begun.



#### Why MA Now?

- Good for the lab too. Outcomes data
  - objectively demonstrates lab value,
  - justifies lab expenditures,
  - Solidifies our position on the healthcare team.

'In skating over thin ice, our safety is in our speed.'

Ralph Waldo Emerson



#### **In Summary**

FFS is going to be replaced by value-based schemes.

Healthcare systems must prepare for this radical new environment in order to stay relevant.

MA offers a powerful way to make this transition by leveraging all institutional data to improve outcomes and inform spending decisions.



#### Acknowledgments

- Brad Brimhall MD MPH, Matt Modleski, Ryan Howard. Orchard Analytics [1]
- Kevin Jordan, Dave Hebert. Marshfield Clinic Information Systems [2]
- Thomas Fritsche MD PhD, Pam Carter, Barb Wirkus. Marshfield Labs [2]
- 1. A subsidiary of Orchard Software. Carmel, IN
- 2. A subsidiary of Marshfield Clinic Health System. Marshfield, WI

